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The burden of type 2 diabetes and its associ-
ated premature morbidity and mortality is rap-
idly growing, and the need for novel efficacious
treatments is pressing. We report here that
serotonin 2C receptor (5-HT2CR) agonists, typi-
cally investigated for their anorectic properties,
significantly improve glucose tolerance and re-
duce plasma insulin inmurinemodels of obesity
and type 2 diabetes. Importantly, 5-HT2CR ago-
nist-induced improvements in glucose homeo-
stasis occurred at concentrations of agonist
that had no effect on ingestive behavior, energy
expenditure, locomotor activity, body weight,
or fat mass. We determined that this primary
effect on glucose homeostasis requires down-
stream activation of melanocortin-4 receptors
(MC4Rs), but not MC3Rs. These findings sug-
gest that pharmacological targeting of 5-HT2CRs
may enhance glucose tolerance independently
of alterations in body weight and that this may
prove an effective and mechanistically novel
strategy in the treatment of type 2 diabetes.
INTRODUCTION
The prevalence of type 2 diabetes has surged in recent
decades. A growing body of work suggests not only that
central neural pathways may play an important role in dys-
regulation of glucose homeostasis but also that these
pathways are potentially amenable to therapeutic manip-
ulation. Pharmacological compounds augmenting the
tone of the neurotransmitter serotonin (5-hydroxytrypta-398 Cell Metabolism 6, 398–405, November 2007 ª2007 Elseviemine, 5-HT) have been extensively investigated for the
treatment of obesity (Dourish, 1995; Simansky, 1996),
a major risk factor for type 2 diabetes. However, the pos-
sibility of a direct role for serotonin in the pathophysi-
ology and treatment of type 2 diabetes has received little
attention.
Serotonin’s effects on physiology and behavior are me-
diated by multiple serotonin receptors (5-HTRs) clustered
into seven distinct families that are widely expressed in the
central and/or peripheral nervous systems (Barnes and
Sharp, 1999). Murine knockout studies reveal that only de-
letion of the gene encoding the 5-HT2C receptor (5-HT2CR,
formerly denoted 5-HT1CR) produces insulin resistance
and type 2 diabetes, with antecedent hyperphagia and
obesity (Bonasera and Tecott, 2000; Nonogaki et al.,
1998; Tecott et al., 1995). These genetic studies demon-
strate that 5-HT2CRs are critical for energy homeosta-
sis but do not indicate whether serotonin generally or
5-HT2CRs specifically have a primary effect on glucose
homeostasis that is dissociable from effects on body
weight. Here, we examined whether 5-HT2CR agonists
are effective in improving glucose tolerance in murine
models of obesity and insulin resistance and whether
these effects can be achieved in the absence of reduc-
tions in food intake and body weight.
RESULTS AND DISCUSSION
5-HT2CR Agonists Improve Glucose Homeostasis
To investigate whether 5-HT2CR stimulation affects glu-
cose homeostasis, hyperinsulinemic diet-induced obese
(DIO) male mice were treated with saline or a subanorectic
dose of the classic 5-HT2CR agonist m-chlorophenyl-
piperazine (mCPP; 1 mg/kg/day) via subcutaneous (s.c.)
osmotic minipump for 14 days. Baseline fasting plasma in-
sulin and blood glucose were determined 2 daysr Inc.
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5-HT2CR Agonists Improve Type 2 Diabetes via MC4RFigure 1. 5-HT2CR Agonists Improve
Glucose Homeostasis and Upregulate
POMC mRNA without Affecting Food
Intake or Body Weight
(A–D) Treatment-induced changes in fasting
plasma insulin and blood glucose, daily food
intake, and body weight were assessed in
diet-induced obese (DIO) mice (n = 10) treated
with saline or mCPP (1 mg/kg/day). Compared
to pretreatment levels (white bars, day 2),
prolonged mCPP infusion (black bars, day 14)
significantly reduced fasting plasma insulin
(A) without altering blood glucose (B). This
concentration of mCPP () had no discernable
effect on food intake (C) or body weight (D)
compared to saline treatment (B).
(E) DIO mice (n = 12, mean body weight = 37 g)
fasted for 12 hrs and then treated with a single
injection of mCPP (1 mg/kg, i.p.; ) 45 min prior
to a glucose load (1 g/kg, i.p.) showed signifi-
cantly improved glucose tolerance compared
to saline (B), an effect blocked by pretreatment
with the 5-HT2CR antagonist RS102221 (RS; 1
mg/kg, i.p.) 30 min prior to mCPP treatment
(>). RS102221 alone (A) had no significant ef-
fect on glucose tolerance.
(F) ob/obmice (n = 6, mean body weight = 52 g,
mean blood glucose = 304 mg/dl) treated with
BVT.X (40 mg/kg/day; black bar) for 7 days
showed a significant enhancement of ARC
POMC mRNA expression and a reduction in
fasting plasma insulin levels compared to
saline-treated counterparts (white bar).
(G and H) A single injection of mCPP (1 mg/kg,
i.p.; ) in 12 hr-fasted DIO mice (n = 36, mean
body weight = 38 g) 45 min prior to a glucose
(1 g/kg, i.p.) (G) or insulin (0.5 U/kg insulin) (H)
load improved glucose and insulin tolerance
compared to saline treatment (B), an effect
blocked by pretreatment with the MC3R/MC4R
antagonist SHU9119 (0.1 nmol, i.c.v.) 30 min
prior to mCPP treatment (>). SHU9119 alone
(A) had no significant effect on glucose or
insulin tolerance.
Data are presented as mean ± SEM. *p < 0.05,
**p < 0.01.preceding pump implantation (day 2) and after 14 days
of saline or mCPP infusion. While saline treatment did
not significantly affect any parameter assessed, mCPP
treatment produced a 49% reduction in fasting plasma in-
sulin (Figure 1A; t(4) = 4.3, p < 0.01) without altering blood
glucose (Figure 1B), food intake (high-fat diet [HFD];
Figure 1C), or body weight (Figure 1D).
We further characterized this effect using the Lepob (ob/
ob) murine model of severe obesity and insulin resistance,
a second 5-HT2CR agonist, and another diet. Mice were
individually housed in Comprehensive Lab Animal Moni-
toring System (CLAMS) chambers recording food intake,
locomotor activity, and energy expenditure. Baseline and
treatment-induced changes in fasting plasma insulin,
fasting blood glucose, and % body fat were also mea-
sured. Hyperinsulinemic male ob/obmice receiving a sub-
anorectic dose of the selective 5-HT2CR agonist BVT.XCell Me(40 mg/kg/day) for 14 days exhibited a 45% improvement
in fasting plasma insulin (see Figure S1A in the Supple-
mental Data available with this article online; t(6) = 3.8,
p < 0.01) with no concomitant change in blood glucose
(Figure S1B), food intake (powdered chow; Figure S1C),
body weight (Figure S1D), % body fat (Figure S1E), loco-
motor activity (Figure S1F), or energy expenditure (VO2;
Figure S1G). These data indicate that 5-HT2CR agonists
ameliorate hyperinsulinemia in mild and severe obesity
independently of alterations in food intake and body
weight.
To establish whether 5-HT2CR activation enhances glu-
cose tolerance, hyperinsulinemic drug-naive DIO mice
were given a single injection of mCPP 45 min prior to a glu-
cose tolerance test (GTT; 1 g/kg glucose, administered in-
traperitoneally [i.p.]). mCPP produced significant improve-
ments in glucose tolerance (Figure 1E; F(3,9) = 488.2,tabolism 6, 398–405, November 2007 ª2007 Elsevier Inc. 399
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tagonist RS102221 (RS; 1 mg/kg, i.p.; Figure 1E) abolished
this effect, confirming that mCPP-induced improvements
in glucose tolerance are 5-HT2CR mediated.
5-HT2CR Agonists Upregulate POMC mRNA
5-HT2CRs are expressed in multiple regions of the central
nervous system (Molineaux et al., 1989). Of particular in-
terest are a population of 5-HT2CRs coexpressed with
neurons producing the endogenous melanocortin recep-
tor agonist a-melanocyte-stimulating hormone (a-MSH)
in the arcuate nucleus of the hypothalamus (ARC) (Heisler
et al., 2002). Pharmacological activation of central mela-
nocortin pathways enhances insulin sensitivity, and over-
expression of the precursor to a-MSH, pro-opiomelano-
cortin (POMC), attenuates insulin resistance in ob/ob
mice (Heijboer et al., 2005; Mizuno et al., 2003; Obici
et al., 2001). This led us to hypothesize that 5-HT2CR ago-
nist-induced improvements in insulin sensitivity involve
stimulation of POMC synthesis in the ARC. To address
this possibility, ob/ob mice were treated with saline or
BVT.X (40 mg/kg/day) via s.c. osmotic minipump for
7 days prior to densitometric quantification of ARC POMC
mRNA with in situ hybridization histochemistry (ISHH).
BVT.X produced a significant increase in the density
of POMC mRNA in the ARC (Figure 1F, left; t(4) = 2.8,
p < 0.05) in association with a significant reduction in fast-
ing plasma insulin (Figure 1F, right; t(4) = 3.5, p < 0.05).
These data suggest that 5-HT2CR agonist-induced im-
provements in hyperinsulinemia may be achieved through
increased a-MSH availability.
The Effect of 5-HT2CR Agonists on Glycemia
Requires Central Melanocortin Receptors
To confirm that the effect of 5-HT2CR agonists on glucose
tolerance is mediated by central melanocortin pathways,
we investigated whether pharmacological blockade of
central melanocortin-3 receptors (MC3Rs) and melano-
cortin-4 receptors (MC4Rs) hinders the ability of mCPP
to enhance glucose tolerance. Specifically, hyperinsuline-
mic DIO mice were pretreated with the MC3R/MC4R
antagonist SHU9119 (0.1 nmol, administered intracere-
broventricularly [i.c.v.]) and then treated with mCPP
(1 mg/kg, i.p.) prior to receiving a glucose bolus (1 g/kg
glucose, i.p.). Once again, a significant improvement in
glucose tolerance was seen after treatment with mCPP
(Figure 1G; F(3,25) = 5.1, p < 0.01), an effect that was com-
pletely abrogated by pretreatment with SHU9119. The
melanocortin antagonist in isolation had no discernible
effect on glycemic excursion.
To assess insulin sensitivity more directly, we next per-
formed an insulin tolerance test (ITT; 0.5 U insulin/kg, i.p.)
in DIO mice and found that mCPP significantly enhanced
the hypoglycemic response to insulin (Figure 1H; F(3,30)
= 3.5, p < 0.05). This effect was fully reversed by i.c.v. pre-
treatment with SHU9119 (0.1 nmol, i.c.v.), which alone had
no significant effect on insulin tolerance. Importantly, mice
undergoing GTTs or ITTs did not have access to food, and
the concentration of mCPP used did not affect appetite400 Cell Metabolism 6, 398–405, November 2007 ª2007 Elsewhen tested in obese mice (Figure S2A). These findings
confirm that 5-HT2CR agonist-induced improvements in
glucose and insulin tolerance are dependent on central
melanocortin pathways and are dissociable from effects
on food intake.
The Effect of 5-HT2CR Agonists Is Mediated
Specifically via MC4Rs
Efforts to discriminate the role of specific melanocortin re-
ceptors indicate that neural outputs important for main-
taining insulin sensitivity are coupled to melanocortin
tone primarily through MC4Rs (Fan et al., 2000; Heijboer
et al., 2005; Huszar et al., 1997; Farooqi et al., 2000).
We thus hypothesized that the mechanism underlying
5-HT2CR agonist-induced insulin sensitization involves in-
creased activation of MC4Rs via upregulation of ARC
POMC mRNA synthesis. We examined this hypothesis us-
ing obese and hyperinsulinemic Mc4r KO mice (Huszar
et al., 1997) and Mc3r KO littermates (Butler et al., 2000)
maintained on HFD to induce comparable obesity and hy-
perinsulinemia. Mice were treated via s.c. osmotic mini-
pump with saline or mCPP (1 mg/kg/day) for 14 days.
mCPP substantially reduced hyperinsulinemia (Figure 2A;
t(4) = 4.3, p < 0.01) without affecting blood glucose (Fig-
ure 2B) and improved glucose tolerance (Figure 2C;
F(1,7) = 387.2, p < 0.001) in Mc3r KO mice to the same ex-
tent observed in wild-type (WT) DIO mice (Figures 1A, 1B,
1E, and 1G), effects achieved without altering food intake
(Figure S2B) or body weight (Figure S2C). Improvements
in glucose tolerance (Figure 2D; F(1,7) = 387.2, p <
0.001) and insulin tolerance (Figure 2E; F(1,7) = 4.05, p <
0.05) were also observed in drug-naive Mc3r KO mice
treated with a single injection of mCPP 45 min prior to
a glucose (1 g/kg, i.p.) or insulin (0.5 U/kg, i.p.) load. In
marked contrast, mCPP produced no discernable effect
in Mc4r KO animals (Figures 2F–2J; Figures S2A, S2D,
and S2E), supporting a specific role for the MC4R in
mCPP-induced improvements in glucose tolerance.
5-HT2CR Agonists Activate Sympathetic
Preganglionic Neurons via MC4Rs
MC4Rs are expressed in brain regions containing both
sympathetic and parasympathetic preganglionic neurons,
each of which has been suggested to modulate glucose
homeostasis (Kishi et al., 2003; Pocai et al., 2005). We in-
vestigated candidate populations of MC4Rs contributing
to 5-HT2CR agonist-induced improvements in glucose
tolerance using Fos-like immunoreactivity (FOS-IR) as a
marker of neuronal activation in Mc4r KO mice and WT lit-
termates treated with saline or mCPP (1 mg/kg, i.p.) prior
to a glucose load (1 g/kg, i.p). Compared to saline treat-
ment, mCPP induced a significant increase in FOS-IR in
POMC neurons in the ARC of both Mc4r KO and WT
mice (Figure S3; t(16) = 5.9, p < 0.001). POMC neurons
have direct projections to the intermediolateral nucleus
of the spinal cord (IML), which contains sympathetic pre-
ganglionic neurons expressing MC4Rs (Elias et al., 1998;
Kishi et al., 2003). Consistent with enhanced sympathetic
activity, we observed a significant increase in FOS-IRvier Inc.
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5-HT2CR Agonists Improve Type 2 Diabetes via MC4RFigure 2. 5-HT2CR Agonists Significantly Reduce Plasma Insulin and Improve Glucose Tolerance inMc3r Knockout but NotMc4r
Knockout Mice
(A–C) Compared to pretreatment levels (white bars, day 2), 14 days of mCPP (1 mg/kg/day; black bars, day 14) treatment in Mc3r KO mice (n = 10,
mean body weight = 43 g) significantly reduced fasting plasma insulin (A) without altering fasting blood glucose (B) and significantly improved glucose
tolerance (C) following a glucose load (1 g/kg, i.p).
(D and E) A single injection of mCPP (1 mg/kg, i.p.; ) in treatment-naive 12 hr-fasted Mc3r KO mice (n = 12, mean body weight = 42 g) 45 min prior to
a glucose (1 g/kg, i.p.) (D) or insulin (0.5 U/kg insulin) (E) load also improved glucose and insulin tolerance compared to saline treatment (B).
(F–H) In contrast, Mc4r KO mice (n = 12, mean body weight = 60 g) treated with mCPP (black bars or ) showed no differences in plasma insulin (F),
fasting blood glucose (G), or glucose tolerance (H) following a glucose load (1 g/kg, i.p.) compared to pretreatment values or saline treatment (white
bars or B).
(I and J) A single injection of mCPP () was similarly ineffective in altering glucose tolerance following a glucose (1 g/kg, i.p.) (I) or insulin (0.5 U/kg
insulin, i.p.) (J) load compared to saline (B) in treatment-naive Mc4r KO mice (n = 12, mean body weight = 59 g).
Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.expression bilaterally in IML neurons of WT mice treated
with mCPP compared to saline (Figures 3A–3D; Figure S4;
t(16) = 4.2, p < 0.001), an effect absent in Mc4r KO mice
(Figures 3E–3F; Figure S4).
Further examination indicated that mCPP induced FOS-
IR in 91% of neurons in the IML staining for choline acetyl-
transferase (ChAT), the enzyme required for acetylcholine
synthesis in sympathetic preganglionic neurons, in WT
mice (Figures 3G–3I) but in <1% of ChAT neurons in
Mc4r KO mice. In other regions associated with auto-
nomic outflow, such as the paraventricular, ventromedial,
dorsomedial, and lateral nuclei of the hypothalamus, theCell Mdorsal motor nucleus of the vagus (DMV), and the nucleus
of the solitary tract, no difference in FOS-IR induction in re-
sponse to mCPP treatment was observed between Mc4r
KO and WT mice (Figure S5). We therefore conclude that
IML MC4R activation is an important component of
5-HT2CR agonist-induced stimulation of the sympathetic
nervous system (SNS). Nevertheless, potential caveats
should be considered when interpreting these findings.
For example, it is formally possible that MC4R deficiency
affects basal and stimulus-induced activity specifically of
IML sympathetic preganglionic neurons. It is also possi-
ble, given the widespread distribution of 5-HT2CRs in theetabolism 6, 398–405, November 2007 ª2007 Elsevier Inc. 401
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istration of higher concentrations of 5-HT2CR agonists
will activate non-MC4R-related pathways that provide in-
puts to preganglionic neurons influencing SNS activity.
Thereby, conditions of MC4R-independent 5-HT2CR ago-
nist-induced stimulation of the SNS would be achieved.
Figure 3. 5-HT2CR Agonist-Induced Improvement in Glucose
Tolerance Is Associated with MC4R-Dependent Increased
FOS-IR in IML ChAT Neurons
Brains from 12 hr dark-cycle-fasted wild-type (WT) and Mc4r KO litter-
mates (n = 18; body weight range = 26–55 g) pretreated with saline or
mCPP (1 mg/kg, i.p.) 45 min preceding a glucose bolus (1 g/kg, i.p.)
were processed for immunohistochemistry.
(A) FOS-IR was not evident in the intermediolateral nucleus of the
spinal cord (IML) following saline treatment.
(B) Magnification of boxed area in (A).
(C–F) In contrast, FOS-IR was consistently evident in mCPP-pre-
treated WT mice (C and D), but not in Mc4r KO mice (E and F).
(G–I) Subsequent analysis revealed that a substantial percentage of
FOS-IR-positive neurons (H) (green fluorescent nuclear stain) were
ChAT-IR positive (I) (red fluorescent cytoplasmic stain). (G) shows
a merged and higher-magnification image of (H) and (I). White arrows
indicate coexpression.
Scale bar in (E) = 250 mM and applies to (A), (C), and (E). Scale bar in
(F) = 25 mM and applies to (B), (D), and (F). Scale bar in (G) = 20 mM.
Scale bar in (I) = 100 mM and applies to (H) and (I).402 Cell Metabolism 6, 398–405, November 2007 ª2007 Elsevie5-HT2CR Agonists Improve Peripheral Insulin
Action via MC4Rs
To further characterize the effect of 5-HT2CR agonists on
insulin action, we compared insulin-induced phosphory-
lation of protein kinase B (PKB) in quadriceps muscle,
liver, and epididymal white adipose tissue (WAT) in DIO
mice pretreated with saline or mCPP (1 mg/kg, i.p.) before
administration of saline or insulin (0.5 U/kg, i.p). mCPP
significantly enhanced PKB phosphorylation in response
to insulin in liver (Figure 4A; F(3,26) = 9.0, p < 0.001) and
muscle (Figure 4B; F(3,26), p < 0.01), but not WAT (Fig-
ure 4C), where significant insulin-induced PKB phosphor-
ylation in the absence of mCPP (F(3,26) = 4.1, p < 0.05)
may have precluded observation of a similar enhance-
ment. To determine whether this effect is MC4R medi-
ated, skeletal muscle was collected from insulinemia-
matched DIO WT, DIO Mc3r KO, and Mc4r KO mice
pretreated with saline or mCPP (1 mg/kg, i.p.) prior to
an insulin load (0.5 U/kg, i.p.). mCPP significantly in-
creased phosphorylation of PKB in both DIO WT (Fig-
ure 4D; t(4) = 3.8, p < 0.05) and DIO Mc3r KO (Figure 4D;
t(5) = 5.6, p < 0.01) mice, an effect absent in Mc4r KO
mice. These findings are concordant with the significant
improvements in glucose tolerance, insulin tolerance,
and fasting hyperinsulinemia seen in DIO WT and DIO
Mc3r KOs, but not in Mc4r KOs, after mCPP treatment
(Figure 1 and Figure 2). Furthermore, we also observed
that prolonged treatment with mCPP (1 mg/kg/day for 7
days, s.c. osmotic minipump) significantly reduced levels
of hepatic phosphoenolpyruvate carboxykinase (PEPCK;
Figure 4E; t(8) = 3.8, p < 0.05) and glucose 6-phosphatase
(G6P; Figure 4F; t(8) = 6.9, p < 0.05) mRNA compared to
saline treatment, providing further evidence for hepatic
insulin sensitization by 5-HT2CR agonist treatment.
Overall, these data support a model wherein 5-HT2CR
agonists improve glucose homeostasis via increased pro-
duction and release of endogenous melanocortin agonists,
with subsequent activation of sympathetic preganglionic
neurons in the IML via stimulation of MC4Rs. While we pro-
vide evidence for enhanced insulin sensitivity in response
to 5-HT2CR agonists, it remains possible that the observed
improved glucose tolerance is a composite of enhanced
insulin secretion and enhanced insulin action in target tis-
sues, though the relative contributions of these remain to
be determined. The potential of 5-HT2CR agonists to ad-
dress both cardinal pathogenic features of type 2 diabetes
mellitus—insulin resistance and b cell failure—is intriguing.
In summary, the identification of new classes of antidia-
betic agents is a clinical imperative. The findings pre-
sented here identify a novel therapeutic application for
a class of pharmacological compounds developed more
than two decades ago. We demonstrate that 5-HT2CR ag-
onists significantly improve glucose tolerance and hyper-
insulinemia in murine models of obesity and type 2 diabe-
tes via an MC4R-dependent mechanism. These findings
not only delineate specific neuronal pathways of relevance
to a highly prevalent metabolic disease but also suggest
that 5-HT2CR agonists may prove an effective and mech-
anistically novel treatment for type 2 diabetes.r Inc.
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5-HT2CR Agonists Improve Type 2 Diabetes via MC4RFigure 4. Effect of 5-HT2CR Agonists on Insulin Signaling
(A–C) A single injection of mCPP (1 mg/kg, i.p.) 45 min prior to insulin (0.5 U/kg, i.p.; gray bars) significantly increased Ser473 phosphorylation of PKB
in liver (A) and skeletal muscle (B), but not white adipose tissue (WAT) (C), compared to saline treatment in 12 hr-fasted DIO mice (n = 30, mean body
weight = 37 g). Representative western blots are displayed above each bar graph.
(D) Supporting a role for the MC4Rs in this effect, DIO WT and DIO Mc3r KO mice (n = 16, mean body weight = 42 g) treated with mCPP (1 mg/kg, i.p.;
black bars) displayed a similar augmentation of insulin (0.5 U/kg, i.p.)-induced Ser473 phosphorylation of PKB in muscle compared to saline-treated
counterparts (white bars), an effect absent in Mc4r KO mice.
(E and F) Moreover, prolonged treatment with mCPP (1 mg/kg/day for 7 days, s.c. minipump) significantly reduced PEPCK (E) and G6P (F) mRNA
expression in the liver of DIO mice (n = 10, mean body weight = 36 g). AU, arbitrary units.
Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.EXPERIMENTAL PROCEDURES
Subjects
Male ob/ob mice (B6.V-Lepob/J), WT littermates, and DIO mice (Re-
search Diets D12331i, 58% kcal fat) were purchased from The Jackson
Laboratory. Male Mc4r KO (Huszar et al., 1997), Mc3r KO (Butler et al.,
2000), and WT littermates were bred by mating heterozygotes. All mice
were on a C57BL/6 background. Mice were individually housed with
food (standard laboratory chow or HFD [Research Diets D12331i])
and water available ad libitum in a light- (12 hr on/12 hr off) and temper-
ature- (21.5C–22.5C) controlled environment unless otherwise noted.
Procedures used were in accordance with the guidelines for the care
and use of animals established by the USA National Institutes of Health
(NIH).
Energy Balance and Basal Blood/Plasma Analysis
Saline, BVT.X (40 mg/kg/day), or mCPP (1 mg/kg/day) were infused
using 7 or 14 day osmotic minipumps (Alzet, Durect Corporation) im-
planted between the scapulae of ob/ob, DIO WT, DIO Mc3r KO, or
Mc4r KO mice. Ad libitum food intake and body weight were measured
daily following the onset of the light cycle. Two days prior to pump im-
plantation (day2) and at the cessation of treatment (day 7 or 14), mice
were fasted for 12 hr during the dark cycle, and blood glucose (Gluc-
ometer Elite, Bayer) and plasma insulin (Mercodia Rat Insulin ELISA,
ALPCO) levels were determined according to manufacturer protocols.
Glucose Tolerance Test and Insulin Tolerance Test
After a 12 hr dark-cycle fast, mice were treated with 1 g/kg glucose or
0.5 U/kg insulin. Blood was sampled from the tail vein, and GTTs andCell MeITTs were performed as described previously (Sutton et al., 2006).
Mice receiving 0.1 nmol SHU9119 or artificial cerebrospinal fluid
(aCSF) prior to GTT or ITT were stereotaxically implanted 2 weeks ear-
lier with an indwelling cannula aimed at the lateral ventricle (relative to
bregma: AP = 0.34 mm, ML = 0.08 mm, DV = 0.16 mm below the
dura) using methods described previously (Heisler et al., 2002).
Western Blots
Following a 12 hr dark-cycle fast, mice were pretreated with saline or
mCPP (1 mg/kg, i.p.); 45 min later, mice were treated with saline or in-
sulin (0.5 U/kg, i.p.). Ten minutes after this, mice were sacrificed, and
skeletal muscle (quadriceps), liver, and epididymal WAT were rapidly
extracted and flash frozen. Tissue samples were then homogenized
in lysis buffer, and following centrifugation, protein concentrations
were determined in the supernatant using methods described previ-
ously (Sutton et al., 2006). Samples containing equal amounts of
protein were denatured and analyzed by SDS-PAGE and western
blotting using phospho-PKB and PKB antibodies (Cell Signaling
Technology).
RNA Isolation and Real-Time PCR Analyses
Total RNA was isolated from tissue samples using RNA STAT-60 (AMS
Biotechnology) and quantified. Five hundred nanograms of each sam-
ple was reverse transcribed using random hexamers and M-MLV
reverse transcriptase (Promega). Expression of G6P and PEPCK was
determined by real-time PCR on an ABI 7900HT Sequence Detection
System (Applied Biosystems) according to the manufacturer’s instruc-
tions, and target values were normalized to 18S rRNA. Real-time PCR
reagents were from Applied Biosystems.tabolism 6, 398–405, November 2007 ª2007 Elsevier Inc. 403
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Tissue Preparation and Histology
Mice under deep anesthesia were perfused transcardially with 0.9%
saline followed by 10% neutral buffered formalin (Sigma). Brains
were removed, immersed in 20% sucrose in phosphate-buffered
saline (PBS; pH 7.0) for 18–36 hr at 4C, sectioned coronally on a
freezing-sliding microtome at 25 mm, and collected in five equal
series.
Immunohistochemistry for FOS-IR
Mirroring the procedure used for the GTT, 12 hr dark-cycle fasted WT
and Mc4r KO littermates were pretreated with saline or mCPP (1 mg/
kg, i.p.) and treated with glucose (1 g/kg, i.p.) 45 min later. Brain tissue
was collected 2 hr later. Standard immunohistochemistry methods
(Elias et al., 1998; Heisler et al., 2002; Kishi et al., 2003) were used
with a monoclonal antibody raised against rabbit c-Fos (1:10,000,
Calbiochem), a biotinylated donkey anti-rabbit secondary antibody
(1:500, Jackson ImmunoResearch Laboratories, Inc.), avidin-biotin
complex (ABC; 1:250, Vector Laboratories), and a solution of 0.04% di-
aminobenzidine tetrahydrochloride (DAB; Sigma) and 0.003% hydro-
gen peroxide in PBS chromogen. Tissues were then mounted onto
slides. Using cresyl violet-stained adjacent sections to clarify nuclear
boundaries, FOS-IR signal throughout the rostrocaudal extent of the
mouse brain and spinal cord was evaluated using a Zeiss Axioskop
2, and qualitative estimates of FOS-IR staining in specific brain regions
were made. Quantitative comparisons of FOS-IR between saline- and
mCPP-treated WT andMc4rKO mice were made in the hypothalamus,
DMV, and IML.
Dual Immunohistochemistry
Standard methods (Zhou et al., 2003) were used to visualize dual-fluo-
rescence imaging of FOS-IR and a-MSH-IR or ChAT-IR. Briefly, adja-
cent sections of brain tissue were incubated with rabbit anti-c-Fos
antibody (1:10,000, Calbiochem) and either sheep anti-a-MSH
(1:5,000, Chemicon) or goat anti-ChAT (1:5,000, Chemicon) serum, a
biotinylated donkey anti-sheep (a-MSH) or donkey anti-goat (ChAT)
secondary antibody (1:500, Jackson ImmunoResearch Laboratories,
Inc.), and a cocktail of Alexa Fluor 594-conjugated streptavidin
(1:1,000, Molecular Probes) and Alexa Fluor 488-conjugated donkey
anti-rabbit (1:300, Molecular Probes). Tissues were mounted onto
Superfrost Plus (Fisher Scientific) slides. A green reaction product
was obtained for Fos, and a red reaction product was obtained for
a-MSH and ChAT. Single- and dual-labeled neurons were quantified
using a Zeiss Axioskop 2 microscope.
ISHH and Densitometry Analysis
Visualization of POMC mRNA in ARC of ob/ob mice treated with saline
or BVT.X (40 mg/kg/day for 7 days) was achieved with ISHH using
methods described previously (Elias et al., 1998; Heisler et al., 2002;
Kishi et al., 2003). Briefly, the POMC riboprobe was synthesized by
in vitro transcription using a T3 polymerase (Ambion) in the presence
of 35S-labeled UTP in accordance with the manufacturer’s protocols.
The 35S-labeled POMC cRNA probe was diluted in a hybridization
solution and allowed to hybridize to tissue at 57C. Following this,
sections were incubated in a 0.002% RNase A solution and rinsed
with decreasing concentrations of sodium citrate buffer in increasing
temperatures (50C–60C). Tissues were then mounted onto slides
and exposed to BioMax MR film (Kodak) for 48–72 hr. Slides were dip-
ped in NTB-2 photographic emulsion (Kodak), exposed for 1 week at
4C, and developed with Kodak fixer and D-19 developer according
to the manufacturer’s instructions. Slides were counterstained with thi-
onin, dehydrated, and coverslipped. Comparisons of POMC mRNA
following saline or BVT.X treatment were made by assessing the
autoradiographic ARC 35S-labled POMC on film as measured with
a light box, a digital camera interface, and NIH Image software. Deter-
mination of the level of bregma for each section of brain tissue repre-
sented on film was made by examining corresponding sections on the
thionin-counterstained slides. ARC 35S-labeled POMC signal within
each section was analyzed by computing the area of signal for
each section throughout the rostrocaudal extent of the ARC minus
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The concomitant effect of the 5-HT2CR agonist BVT.X (40 mg/kg/day
for 14 days, s.c. minipump) on ad libitum food intake, locomotor activ-
ity, and oxygen consumption was assessed in male ob/ob mice
housed in CLAMS chambers (Columbus Instruments). CLAMS cham-
bers are 1 l rectangular acrylic cages with a source of powdered labo-
ratory chow linked to a balance for food intake determination, a photo-
beam array surround for locomotor activity determination, and an
indirect open-circuit calorimeter for oxygen consumption/respiratory
exchange ratio data collection. Data are collected through a computer
interface. Mice were acclimated to the chambers prior to the start of
the study. Once stable feeding patterns comparable to home-cage
conditions were evident, experimental treatment was initiated.
Dual-Energy X-Ray Absorptiometry
To measure the effect of saline and the 5-HT2CR agonist BVT.X
(40 mg/kg/day for 14 days, s.c. minipump) on body composition,
% body fat was assessed via dual-energy X-ray absorptiometry (Lunar
PIXImus, MEC Lunar Corp.) immediately before minipump implanta-
tion (day 0) and after minipump extraction (day 14) in ob/ob mice as-
sessed in CLAMS chambers.
Drugs
Mice were treated with 0.9% pyrogen-free saline, the 5-HT2CR ago-
nists BVT.X (kindly provided by Biovitrum) or mCPP (Sigma), or the
5-HT2CR antagonist RS102221 (Tocris Cookson). Drugs were dissolved
in 0.9% saline and administered i.p. in 10 ml/g of body weight or s.c. via
osmotic minipumps. The MC3R/MC4R antagonist SHU9119 (Sigma)
was dissolved in aCSF and administered i.c.v. at a concentration of
0.1 nmol in a 5 ml volume.
Data Analysis
Food intake, body weight, plasma insulin, and blood glucose data
were assessed via dependent t test or repeated-measures analysis
of variance (RM ANOVA). For GTTs and ITTs, differences between
treatments were assessed via RM ANOVA. Treatment-induced changes
in FOS-IR expression in brain and spinal cord were analyzed via inde-
pendent samples t test. PKB phosphorylation in response to insulin
treatment in liver, muscle, and WAT was analyzed via independent
samples t test or one-way ANOVA. Differences between treatments
in the expression of POMC, PEPCK, and G6P mRNAs were analyzed
via independent samples t test. Post hoc tests were performed using
Tukey’s test. t test results are presented as t(degrees of freedom sub-
jects) = value of t, p value. ANOVA results are presented as F(degrees
of freedom between groups, degrees of freedom within group) = value
of F, p value. For all analyses, significance was assigned at the p %
0.05 level. Data are presented as mean ± SEM.
Supplemental Data
Supplemental Data include five figures and can be found with this
article online at http://www.cellmetabolism.org/cgi/content/full/6/5/
398/DC1/.
ACKNOWLEDGMENTS
The authors were supported by the following: J.J.R., British Heart
Foundation; D.D.L., the Gates Cambridge Trust; L.J.O., NIDDK
R3728082 (through J.S. Flier), the Jalmari and Rauha Ahokas Founda-
tion, and the Finnish Foundation for Cardiovascular Research; P.G.C.,
BBSRC C505291; J.K.E., NIMH R01 MH61583, NIDDK R01 53301,
NIDDK P01 DK56116, and a Smith Family Pinnacle Award from the
American Diabetes Association; A.A.B., NIDDK R21 DK068330 and
the American Diabetes Association; and L.K.H., NIDDK R01
DK065171, the American Diabetes Association, the Wellcome Trust,
and the Boston Obesity Nutrition Research Center. A.A.B. is a share-
holder of Orexigen Therapeutics, Inc., and a consultant for Ipsen,
Inc., companies that may have a commercial interest in the results of
this research.ier Inc.
Cell Metabolism
5-HT2CR Agonists Improve Type 2 Diabetes via MC4RReceived: November 28, 2006
Revised: August 16, 2007
Accepted: October 15, 2007
Published: November 6, 2007
REFERENCES
Barnes, N.M., and Sharp, T. (1999). A review of central 5-HT receptors
and their function. Neuropharmacology 38, 1083–1152.
Bonasera, S.J., and Tecott, L.H. (2000). Mouse models of serotonin
receptor function: toward a genetic dissection of serotonin systems.
Pharmacol. Ther. 88, 133–142.
Butler, A.A., Kesterson, R.A., Khong, K., Cullen, M.J., Pelleymounter,
M.A., Dekoning, J., Baetscher, M., and Cone, R.D. (2000). A unique
metabolic syndrome causes obesity in the melanocortin-3 receptor-
deficient mouse. Endocrinology 141, 3518–3521.
Dourish, C.T. (1995). Multiple serotonin receptors: opportunities for
new treatments for obesity? Obes. Res. 3 (Suppl 4), 449S–462S.
Elias, C.F., Lee, C., Kelly, J., Aschkenasi, C., Ahima, R.S., Couceyro,
P.R., Kuhar, M.J., Saper, C.B., and Elmquist, J.K. (1998). Leptin acti-
vates hypothalamic CART neurons projecting to the spinal cord. Neu-
ron 21, 1375–1385.
Fan, W., Dinulescu, D.M., Butler, A.A., Zhou, J., Marks, D.L., and Cone,
R.D. (2000). The central melanocortin system can directly regulate
serum insulin levels. Endocrinology 141, 3072–3079.
Farooqi, I.S., Yeo, G.S., Keogh, J.M., Aminian, S., Jebb, S.A., Butler,
G., Cheetham, T., and O’Rahilly, S. (2000). Dominant and recessive in-
heritance of morbid obesity associated with melanocortin 4 receptor
deficiency. J. Clin. Invest. 106, 271–279.
Heijboer, A.C., van den Hoek, A.M., Pijl, H., Voshol, P.J., Havekes,
L.M., Romijn, J.A., and Corssmit, E.P. (2005). Intracerebroventricular
administration of melanotan II increases insulin sensitivity of glucose
disposal in mice. Diabetologia 48, 1621–1626.
Heisler, L.K., Cowley, M.A., Tecott, L.H., Fan, W., Low, M.J., Smart,
J.L., Rubinstein, M., Tatro, J.B., Marcus, J.N., Holstege, H., et al.
(2002). Activation of central melanocortin pathways by fenfluramine.
Science 297, 609–611.Cell MeHuszar, D., Lynch, C.A., Fairchild-Huntress, V., Dunmore, J.H., Fang,
Q., Berkemeier, L.R., Gu, W., Kesterson, R.A., Boston, B.A., Cone,
R.D., et al. (1997). Targeted disruption of the melanocortin-4 receptor
results in obesity in mice. Cell 88, 131–141.
Kishi, T., Aschkenasi, C.J., Lee, C.E., Mountjoy, K.G., Saper, C.B., and
Elmquist, J.K. (2003). Expression of melanocortin 4 receptor mRNA in
the central nervous system of the rat. J. Comp. Neurol. 457, 213–235.
Mizuno, T.M., Kelley, K.A., Pasinetti, G.M., Roberts, J.L., and Mobbs,
C.V. (2003). Transgenic neuronal expression of proopiomelanocortin
attenuates hyperphagic response to fasting and reverses metabolic
impairments in leptin-deficient obese mice. Diabetes 52, 2675–2683.
Molineaux, S.M., Jessell, T.M., Axel, R., and Julius, D. (1989). 5-HT1c
receptor is a prominent serotonin receptor subtype in the central
nervous system. Proc. Natl. Acad. Sci. USA 86, 6793–6797.
Nonogaki, K., Strack, A.M., Dallman, M.F., and Tecott, L.H. (1998).
Leptin-independent hyperphagia and type 2 diabetes in mice with
a mutated serotonin 5-HT2C receptor gene. Nat. Med. 4, 1152–1156.
Obici, S., Feng, Z., Tan, J., Liu, L., Karkanias, G., and Rossetti, L.
(2001). Central melanocortin receptors regulate insulin action. J. Clin.
Invest. 108, 1079–1085.
Pocai, A., Obici, S., Schwartz, G.J., and Rossetti, L. (2005). A brain-
liver circuit regulates glucose homeostasis. Cell Metab. 1, 53–61.
Simansky, K.J. (1996). Serotonergic control of the organization of feed-
ing and satiety. Behav. Brain Res. 73, 37–42.
Sutton, G.M., Trevaskis, J.L., Hulver, M.W., McMillan, R.P., Markward,
N.J., Babin, M.J., Meyer, E.A., and Butler, A.A. (2006). Diet-genotype
interactions in the development of the obese, insulin-resistant pheno-
type of C57BL/6J mice lacking melanocortin-3 or -4 receptors. Endo-
crinology 147, 2183–2196.
Tecott, L.H., Sun, L.M., Akana, S.F., Strack, A.M., Lowenstein, D.H.,
Dallman, M.F., and Julius, D. (1995). Eating disorder and epilepsy in
mice lacking 5-HT2c serotonin receptors. Nature 374, 542–546.
Zhou, L., Furuta, T., and Kaneko, T. (2003). Chemical organization of
projection neurons in the rat accumbens nucleus and olfactory tuber-
cle. Neuroscience 120, 783–798.tabolism 6, 398–405, November 2007 ª2007 Elsevier Inc. 405
